These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 19632838)

  • 1. Human plasma-mediated hypoxic activation of indolequinone-based naloxone pro-drugs.
    Huang B; Tang S; Desai A; Cheng XM; Kotlyar A; Van Der Spek A; Thomas TP; Baker JR
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5016-20. PubMed ID: 19632838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
    Xu S; Yao H; Pei L; Hu M; Li D; Qiu Y; Wang G; Wu L; Yao H; Zhu Z; Xu J
    Eur J Med Chem; 2017 May; 132():310-321. PubMed ID: 28395199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone pro-drug rescues morphine induced respiratory depression in Sprague-Dawley rats.
    Wallisch M; El Rody NM; Huang B; Koop DR; Baker JR; Olsen GD
    Respir Physiol Neurobiol; 2012 Jan; 180(1):52-60. PubMed ID: 22027217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INDQ/NO, a bioreductively activated nitric oxide prodrug.
    Sharma K; Iyer A; Sengupta K; Chakrapani H
    Org Lett; 2013 Jun; 15(11):2636-9. PubMed ID: 23659457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bexarotene prodrugs: targeting through cleavage by NQO1 (DT-diaphorase).
    Schäfer A; Burstein ES; Olsson R
    Bioorg Med Chem Lett; 2014 Apr; 24(8):1944-7. PubMed ID: 24666648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-selective activation of 5-fluorodeoxyuridine prodrug possessing indolequinone structure: radiolytic reduction and cytotoxicity characteristics.
    Tanabe K; Makimura Y; Tachi Y; Imagawa-Sato A; Nishimoto S
    Bioorg Med Chem Lett; 2005 May; 15(9):2321-4. PubMed ID: 15837317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release.
    Huang B; Desai A; Tang S; Thomas TP; Baker JR
    Org Lett; 2010 Apr; 12(7):1384-7. PubMed ID: 20192275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzymatic activation of indolequinone-substituted 5-fluorodeoxyuridine prodrugs in hypoxic cells.
    Jiho Y; Kurihara R; Kawai K; Yamada H; Uto Y; Tanabe K
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1304-1307. PubMed ID: 30975626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
    Chen S; Knox R; Lewis AD; Friedlos F; Workman P; Deng PS; Fung M; Ebenstein D; Wu K; Tsai TM
    Mol Pharmacol; 1995 May; 47(5):934-9. PubMed ID: 7746280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase.
    Hernick M; Flader C; Borch RF
    J Med Chem; 2002 Aug; 45(16):3540-8. PubMed ID: 12139465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells.
    Reigan P; Colucci MA; Siegel D; Chilloux A; Moody CJ; Ross D
    Biochemistry; 2007 May; 46(20):5941-50. PubMed ID: 17455910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naloxone-6 alpha-spirohydantoin: a long-acting opiate antagonist.
    Alexander GJ; Chatterjie N
    Neurochem Res; 1989 Dec; 14(12):1229-34. PubMed ID: 2560821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonism by naloxone of narcotic-induced respiratory depression and analgesia.
    McGilliard KL; Takemori AE
    J Pharmacol Exp Ther; 1978 Nov; 207(2):494-503. PubMed ID: 30841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under hypoxia.
    Begleiter A; Robotham E; Leith MK
    Mol Pharmacol; 1992 Apr; 41(4):677-82. PubMed ID: 1373799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indolequinone antitumour agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase.
    Newsome JJ; Swann E; Hassani M; Bray KC; Slawin AM; Beall HD; Moody CJ
    Org Biomol Chem; 2007 May; 5(10):1629-40. PubMed ID: 17571194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the abstinence-like overshoot following reversal of the potent 19-isoamyl derivative of etorphine with naloxone. A comparison with the opioids fentanyl and alfentanil.
    Freye E; Neruda B; Smith OW
    Arzneimittelforschung; 1997 Jan; 47(1):6-9. PubMed ID: 9037435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of naloxone on the induction of immediately early genes following oxygen- and glucose-deprivation in PC12 cells.
    Huang HM; Yu JY; Ou HC; Jeng KC
    Neurosci Lett; 2008 Jun; 438(2):252-6. PubMed ID: 18457920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of antagonists of narcotic-induced respiratory depression. A brief review.
    Bowdle TA
    Acute Care; 1988; 12 Suppl 1():70-6. PubMed ID: 3278495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under acidic conditions.
    Begleiter A; Leith MK
    Mol Pharmacol; 1993 Jul; 44(1):210-5. PubMed ID: 8341273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.